Men with Impaired Fasting Glucose at Risk of Diabetes During Chemotherapy, Study Reveals

A recent study has revealed that as many as 6% of cancer patients receiving chemotherapy with dexamethasone develop new-onset diabetes, and the risk is evident in men with impaired fasting glucose (IFG).

Photo: Impaired Fasting Glucose | InStyleHealth


What is Impaired Fasting Glucose (IFG)?

Impaired fasting glucose or also referred to as impaired fasting glycemia, can also be considered as pre-diabetes or metabolic syndrome. IFG happens when blood glucose levels in the body are elevated during periods of fasting, although not enough to trigger a diagnosis of diabetes.

A person with impaired fasting glucose is not able to process glucose as efficiently as they should be able to in a healthy body.

A multicenter group study involved 299 diabetes-free patients with breast or colorectal cancer with average age of >18 years and scheduled to undergo 4 – 8 cycles of adjuvant chemotherapy. The endpoints were the incidence, remission rate, and independent determinants of new-onset diabetes during chemotherapy.

There were 270 patients with average age of 51 years who completed the follow up (average, 39 months). Seventeen patients (6.3%) developed diabetes within an average of 90 days after the initiation of treatment.

New-onset diabetes risk was about 15 times higher among men vs women and 8 times greater among those with impaired fasting glucose (IFG) at baseline.

Diabetes remission occurred in 11 out of 17 patients (64.7%), six months after the patients completed the chemotherapy. Remission was correlated with a significantly higher C-peptide level at baseline.

The findings, however, underscore the significance of close monitoring of hyperglycemia in cancer patients on chemotherapy with steroids, especially in men with impaired fasting glucose (IFG).

For complete details of the study, click here.

 


Source: Diabetes Res Clin Pract 2021;doi:10.1016/j.diabres.2021.108751

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post